{"id":"NCT01709578","sponsor":"Sanofi","briefTitle":"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","officialTitle":"A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-10-18","resultsPosted":"2017-08-08","lastUpdate":"2017-08-08"},"enrollment":546,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Sarilumab","otherNames":["SAR153191","REGN88"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"hydroxychloroquine","otherNames":[]},{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"sulfasalazine","otherNames":[]},{"type":"DRUG","name":"leflunomide","otherNames":[]}],"arms":[{"label":"Placebo q2w","type":"PLACEBO_COMPARATOR"},{"label":"Sarilumab 150 mg q2w","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg q2w","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for:\n\n* reduction of signs and symptoms at Week 24 and\n* improvement of physical function at Week 12\n\nin participants with active rheumatoid arthritis (RA) who were inadequate responders or intolerant to tumor necrosis factor alpha (TNF-α) antagonists.\n\nSecondary Objectives:\n\nThe secondary objectives were to investigate the effects of SAR153191 (REGN88) when added to DMARD therapy, in participants with active RA who were inadequate responders or intolerant to TNF-α antagonists, for:\n\n* Reduction of signs and symptoms at Week 12;\n* Improvement in physical function at Week 24;\n* Improvement in disease activity score as measured by other American College of Rheumatology (ACR) derived components at Weeks 12 and 24;\n* Improvement in quality of life as measured by participant reported outcomes (PROs) at intermediate visits and Week 24.\n\nTo assess the exposure of sarilumab added to DMARD therapy in this population.\n\nTo assess the safety of sarilumab in this population.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo q2w","deltaMin":33.7,"sd":null},{"arm":"Sarilumab 150 mg q2w","deltaMin":55.8,"sd":null},{"arm":"Sarilumab 200 mg q2w","deltaMin":60.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":196,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","Colombia","Czechia","Ecuador","Germany","Greece","Guatemala","Hungary","Israel","Italy","Lithuania","Mexico","New Zealand","Peru","Poland","Portugal","Romania","Russia","Slovakia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["27860410","36413080","36008838","34519964","33871596","32907617","32522251","30877216","29556418","28326189"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":181},"commonTop":["Neutropenia","Urinary tract infection","Nasopharyngitis","Hypertriglyceridaemia","Injection site erythema"]}}